FindTrial
Sign In

Solriamfetol 150 mg

DRUG5 trials

Sponsors

Massachusetts General Hospital, Axsome Therapeutics, Inc.

Conditions

ADHDAttention Deficit Hyperactivity DisorderBinge-Eating DisorderExcessive SleepinessMajor Depressive Disorder With Excessive Daytime Sleepiness SymptomsShift-work Disorder

Phase 2

A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults
CompletedNCT04839562
Massachusetts General HospitalAttention Deficit Hyperactivity Disorder
Start: 2021-08-06End: 2023-01-27Updated: 2024-03-04

Phase 3

A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)
CompletedNCT05972044
Axsome Therapeutics, Inc.ADHD
Start: 2023-07-06End: 2025-03-14Updated: 2026-02-10
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
RecruitingNCT06413433
Axsome Therapeutics, Inc.Binge-Eating Disorder
Start: 2024-04-26End: 2026-12-01Target: 450Updated: 2026-07-28
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
RecruitingNCT06568367
Axsome Therapeutics, Inc.Excessive Sleepiness, Shift-work Disorder
Start: 2024-08-01End: 2026-12-01Target: 520Updated: 2026-07-24
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
RecruitingNCT07484217
Axsome Therapeutics, Inc.Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Start: 2026-02-23End: 2028-12-01Target: 508Updated: 2026-07-24

Related Papers

Solriamfetol for Attention-Deficit/Hyperactivity Disorder in Adults
The Journal of Clinical Psychiatry2023-10-0513 citations